Table 2.

Single factor correlation analysis of each factor and C/D

Item	A		B		C		D
	r	P	r	P	r	P	r	P
Age	− 0.6674	< 0.0001**	− 0.6620	< 0.0001**	− 0.7613	< 0.0001**	− 0.7176	< 0.0001**
Weight	− 0.6693	< 0.0001**	− 0.6740	< 0.0001**	− 0.7421	< 0.0001**	− 0.6993	< 0.0001**
Surface area	− 0.6736	< 0.0001**	− 0.6779	< 0.0001**	− 0.7232	< 0.0001**	− 0.6908	< 0.0001**
WBC	0.2414	0.0011**	0.1320	0.1074	0.2745	0.0024**	0.1653	0.1094
RBC	− 0.0102	0.8915	0.1465	0.0736	0.1301	0.1567	0.0029	0.9780
PLT	0.0103	0.8908	0.0516	0.5307	0.1516	0.0983	0.0409	0.6937
HGB	− 0.2156	0.0037**	− 0.2319	0.0043**	− 0.4086	< 0.0001**	− 0.2515	0.0139*
AST	0.4393	< 0.0001**	0.5245	< 0.0001**	0.5234	< 0.0001**	0.4905	< 0.0001**
ALT	0.3066	< 0.0001**	0.3985	< 0.0001**	0.2602	0.0041**	0.3720	0.0002**
TBIL	− 0.1083	0.1479	− 0.2462	0.0024**	− 0.2354	0.0096**	− 0.2577	0.0117*
ALB	− 0.2286	0.0020**	− 0.3576	< 0.0001**	− 0.1748	0.0562	− 0.0442	0.6704
CREA	− 0.5661	< 0.0001**	− 0.6551	< 0.0001**	− 0.6555	< 0.0001**	− 0.6612	< 0.0001**

Group A, B, C, and D: 1 week after sirolimus (group A), 2 weeks after sirolimus (group B), 4 weeks after sirolimus(group C), and 12 weeks after sirolimus (group D)

*The Pearson correlation analysis revealed a significant relationship between X and the corrected sirolimus C/D

r Pearson correlation coefficient, P P-value, WBC leukocyte count, RBC erythrocyte count, PLT platelet count, HGB hemoglobin, AST aspartate aminotransferase, ALT alanine aminotransferase, TBIL total bilirubin, ALB albumin, CREA creatinine